ELIQUENT Life Sciences Acquires Truliant Consulting to Expand Pharmacovigilance Platform
ELIQUENT Life Sciences, a global leader in regulatory, quality, and safety consulting, has announced the strategic acquisition of Truliant Consulting, a highly regarded pharmacovigilance, risk management, and regulatory compliance advisory firm. This acquisition strengthens ELIQUENT’s position as a premier provider of comprehensive services across every stage of the product lifecycle for life sciences companies.
“We are excited to welcome Truliant Consulting to the ELIQUENT family,” said Tim Dietlin, Chief Executive Officer of ELIQUENT Life Sciences. “Truliant has earned a strong reputation for its high-quality pharmacovigilance and risk management solutions. With their specialized knowledge, technology-driven approach, and operational scalability, this acquisition will significantly enhance our pharmacovigilance platform and enable us to provide our clients with an exceptional partner for regulatory success.”
The acquisition of Truliant follows ELIQUENT’s recent appointment of Shelley Gandhi, a globally recognized pharmacovigilance leader with over 30 years of risk management expertise. Gandhi’s extensive experience and insight into regulatory expectations will play a crucial role in guiding companies through complex safety assessments and regulatory reporting requirements. Together with the acquisition of Truliant, Gandhi’s leadership further strengthens ELIQUENT’s commitment to building a world-class pharmacovigilance platform, combining industry expertise, cutting-edge technology, and scalable solutions to better serve global life sciences innovators.
“Since our founding, Truliant has been at the forefront of delivering impactful pharmacovigilance and risk management consulting to clients around the world,” said Jamie Portnoff, CEO and Co-Founder of Truliant Consulting. “Joining forces with ELIQUENT Life Sciences represents an exciting new chapter for us. We look forward to expanding our expertise within a team that brings complementary strengths and shared values. Together, we will drive innovation and improve outcomes for our clients.”
The integration of Truliant’s technology-driven service offerings enhances ELIQUENT’s existing pharmacovigilance platform, enabling the firm to provide a broader range of solutions. These include process optimization, integration of cutting-edge technologies, and the ability to build scalable pharmacovigilance programs. The combined capabilities deliver a full spectrum of strategic and operational tools, expertise, and technology, empowering clients to effectively manage risk and maintain compliance across key areas, including:
Risk Management: Proactive strategies to identify, assess, and mitigate safety risks, ensuring alignment with global regulatory requirements.
Operational Efficiency: Streamlined processes and scalable workflows designed to reduce complexity and improve performance, allowing clients to focus on core business objectives.
Compliance Readiness: Comprehensive support to ensure inspection readiness and alignment with regulatory agencies worldwide, helping clients maintain market authorization for their products.
Safety Oversight: Robust governance and scientific leadership to maintain product safety and ensure regulatory accountability at all stages of the product lifecycle.
Technology Integration: Expert guidance in selecting, implementing, and optimizing pharmacovigilance systems for seamless and compliant operations, ensuring that technology adds real value to safety management practices.
Scalable Solutions: Flexible support models that evolve with clients’ business needs, providing the right expertise at the right time to accommodate growth and complexity.
The addition of Truliant Consulting is expected to be a game-changer for ELIQUENT’s pharmacovigilance platform, allowing the firm to deliver even more value to life sciences companies seeking to meet the stringent regulatory demands of the global market.
About Truliant Consulting:
Founded in 2021 and based in Baltimore, Maryland, Truliant Consulting is a women-owned business specializing in pharmacovigilance and risk management consulting for the life sciences industry. Truliant’s team consists of highly experienced professionals dedicated to delivering innovative, efficient, and compliant solutions for clients in the pharmaceutical, biotechnology, and medical device sectors.
About ELIQUENT Life Sciences:
ELIQUENT Life Sciences is a global consulting group that provides regulatory affairs, pharmacovigilance, quality, and compliance solutions to clients in the life sciences industry. The company serves pharmaceutical, biotechnology, and medical device companies across therapeutic modalities, phase-based pathways, and major global markets. With a team of industry experts, regulatory leaders, and technical specialists, ELIQUENT delivers global solutions to help companies bring new therapies to market and maintain their market authorization. The firm’s growth is supported by GHO Capital, a European specialist investor in healthcare.
ELIQUENT’s acquisition of Truliant Consulting marks a significant milestone in the company’s ongoing efforts to enhance its pharmacovigilance and risk management capabilities, positioning the firm as a leader in providing end-to-end support for the life sciences industry.
